Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations

Kaavya Narasimhalu,Yoong Kwei Ang,Doreen Su Yin Tan,Deidre Anne De Silva,Kelvin Bryan Tan

DOI: https://doi.org/10.1007/s40261-020-00970-y

2020-09-21

Clinical Drug Investigation

Abstract:Patients with ischemic stroke are often treated with clopidogrel monotherapy as part of secondary stroke prevention. The prevalence of loss of function (LOF) mutations in the CYP2C19 gene is higher in Asians than in Western populations. Patients with loss of function (LOF) mutations are at risk for poorer secondary outcomes when prescribed clopidogrel.

pharmacology & pharmacy